Veterans with substance use disorders smoke at extraordinarily high rates and have high rates of smoking-related death and disease. It is essential to provide tobacco treatment for Veterans with substance use disorders, but there are unfortunately low rates of smoking treatment engagement within the VA for those with substance use disorders. The goal of this project is to generate preliminary evidence for a smoking intervention program called "Concurrent Substance and Tobacco Outpatient Program" or Co-STOP. Co-STOP aims to increase tobacco treatment use and effectiveness for Veterans in outpatient substance use treatment. We hypothesize that Co-STOP, relative to standard tobacco treatment, will increase tobacco treatment use and quit attempts. This research will help the VA develop effective strategies to promote smoking treatment use and abstinence in Veterans with substance use disorders who smoke, thereby improving rates of morbidity and mortality in Veterans with substance use disorders.

Start Date01 Apr 2027

Sponsor / Collaborator

VA Office of Research and Development

[+1]

NCT07754578

/ Not yet recruitingPhase 2

High-Dose Nicotine Replacement Therapy for Quitting Cigarettes and E-cigarettes

This randomized clinical trial evaluates the effectiveness of augmented-dose combination nicotine replacement therapy (NRT) versus standard-dose NRT and no-NRT control for cessation of dual combustible cigarette (CC) and electronic cigarette (EC) use. Adults who currently engage in dual use and are motivated to quit both products will be assigned to one of three 12-week interventions: (1) no pharmacotherapy (behavioral support only), (2) standard-dose NRT (21 mg nicotine patch + 4 mg lozenges, 5-20/day), or (3) augmented-dose NRT (21 mg + 14 mg patches + 4 mg lozenges, 5-30/day). All groups receive evidence-based behavioral support through the EX Program. Primary outcomes include biochemically confirmed dual abstinence and CC-only abstinence at 12 and 24 weeks. A subset of participants will provide blood and saliva samples to assess DNA damage biomarkers associated with tobacco use and cessation.

Start Date10 Oct 2026

Sponsor / Collaborator

The Medical University of South Carolina

[+2]

NCT06811038

/ Not yet recruitingPhase 3

Providing Nicotine Replacement Therapy to Enhance the Efficacy of a Smoking Cessation Smartphone App for Hispanic Adults

This phase III trial compares a smartphone application with or without nicotine replacement therapy in improving smoking cessation among Hispanic adults who would like to quit smoking. The iCanQuit smartphone application focuses on skills for managing urges, motivation, and relapse prevention with personalized quit plans. Nicotine replacement therapy works by giving small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking without any of the other harmful chemicals found in tobacco products.

Start Date15 Sep 2026

Sponsor / Collaborator

Fred Hutchinson Cancer Center

[+1]

100 Clinical Results associated with Nicotine

100 Translational Medicine associated with Nicotine

100 Patents (Medical) associated with Nicotine

34,200

Literatures (Medical) associated with Nicotine

31 Dec 2026·European Journal of Psychotraumatology

Reductions in cigarette use in a pilot intervention for opioid use disorder and PTSD

Article

Author: Saraiya, Tanya C. ; Hameed, Sara ; Worley, Ariel ; Johal, Priya K. ; Singal, Sonali

Background: Posttraumatic stress disorder (PTSD) symptoms are associated with increased substance misuse, including cigarettes and opioids. People who use opioids often report a desire to quit cigarettes, but little research has explored concurrent reductions in opioid and cigarette use in treatments for PTSD and substance use disorders.Objective: This exploratory study examined changes in cigarette use in a pilot study of an integrated psychotherapy for co-occurring opioid use disorder (OUD) and PTSD.Method: Daily cigarette use was measured using the Timeline Followback at 30 days before baseline, during weekly intervention sessions, and at 1-month follow-up. Bootstrapped linear mixed effect models tested for self-reported reductions in cigarette use across a subsample (n=4) who reported using cigarettes at baseline.Results: Results showed reductions in the average number of cigarettes used per day (CPD) between baseline and 1-month follow-up (B=-.93, SE=.41, p=.04) from an average of 17.06 (SD=15.32) CPD at baseline to an average of 8.07 (SD=9.28) CPD at follow-up. Additionally, participants reported high satisfaction with the intervention, with a mean score of 28.33 (SD=2.78) on the Client Satisfaction Questionnaire and all participants completed the intervention.Conclusions: Exploratory findings suggest that the integrated treatment for OUD/PTSD may have assisted in reductions of co-occurring cigarette use. Notable limitations include the study's small sample size, lack of a control group, and lack of nicotine product-specific self-report and biological measures. Although exploratory, observed changes suggest future work should explore concurrent reductions in opioid and cigarette use in randomized clinical trials for OUD/PTSD.

01 Dec 2026·Journal of Cardiovascular Translational Research

Towards Neoatherosclerosis: A Porcine Model for Enhanced Device Testing

Article

Author: Speck, Ulrich ; Haase, Tobias ; Hauptmann, Ralf ; Gemeinhardt, Ole ; Schannor, Mathias ; Xie, Jing ; Loechel, Melanie ; Bettink, Stephanie

Abstract:

The porcine in-stent stenosis model has been essential for developing drug-coated devices but does not replicate the hyperlipidemic, pro-atherogenic conditions driving neoatherosclerosis. We aimed to establish a practical porcine model for testing endovascular therapies targeting neoatherosclerosis. Juvenile pigs were fed a high-fat, nicotine-supplemented diet (HFDN). After two weeks, bare-metal stents were implanted in coronary and peripheral arteries; controls received a standard diet. Four weeks later, stented, and non-stented artery segments were analyzed. HFDN feeding induced elevated serum LDL and cotinine. At follow-up, in-stent late lumen loss was significantly greater in peripheral arteries (A. iliaca: 2.3 ± 0.6 vs. 1.1 ± 0.5 mm; A. femoralis: 3.4 ± 1.2 vs. 2.0 ± 0.4 mm), but not coronary arteries. HFDN-fed pigs showed distinct signs of early neoatherosclerosis, including peri-strut foam cell accumulations and atheroma formation. Elemental imaging and chemical analysis confirmed increased calcium phosphate deposition in arteries of HFDN-fed pigs. This straightforward protocol enables testing of devices aimed at preventing or treating neoatherosclerosis.

01 Dec 2026·Toxicology reports

Comparison of effects of charcoal versus electric heating of waterpipe tobacco on carbon monoxide levels; cardiovascular measures; benzene, pyrene, and nicotine uptake; and subjective reactions

Article

Author: Liles, Sandy ; Zaki, Flora K ; Kassem, Noura O ; Kassem, Nada O F

Toxicants are released from charcoal burned to heat waterpipe tobacco (WPT) and from WPT itself. This natural home setting trial tested a strategy to reduce harm of WPT use by comparing the effects of charcoal versus electric heating of WPT on outcome measures of toxicity. Fifty WPT smokers and 25 non-smokers (controls) participated. Within-subjects measures were collected in charcoal heated and in electric heated WPT smoking sessions. Pre-to-post differences in levels of ambient carbon monoxide (CO), exhaled CO, and heart rate were significantly lower when WPT was electrically heated; there were no differences for urinary biomarkers of nicotine, benzene and pyrene uptake. Comparing levels of controls to post smoking levels of urinary biomarkers of exposure to WPT indicated that electric heating of WPT versus charcoal heating did not significantly reduce exposure to the addictive drug nicotine or the toxicant pyrene, but did significantly reduce exposure to the carcinogenic compound benzene. Furthermore, we found visual evidence of charred WPT from electric sessions, suggesting excessively heated WPT. Participants reported smoking electric-heated WPT was less appealing; harsher and hurt their throat; but healthier and cleaner. To prevent negative subjective reactions from smokers and potential adverse health effects, electric heating devices should be regulated to prevent overheating and excessive thermal degradation of WPT. The findings also inform a harm reduction strategy, particularly for children living in homes of WPT smokers: smokers who use burning charcoal to heat WPT should avoid smoking indoors, as ambient CO levels proved significantly higher indoors than outdoors.

230

News (Medical) associated with Nicotine

09 Sep 2026

·www.prnewswire.com

Global Action to End Smoking Awards Grant to University of Chicago to Increase Living Kidney Donation Through Smoking Cessation

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Global Action to End Smoking is pleased to announce an innovative grant to The University of Chicago that aims to increase the number of viable living kidney donors by offering comprehensive smoking cessation support, including tobacco harm reduction, for donors who smoke. Continue Reading The Project Donor team at the Illinois Walk for Kidneys. Image courtesy of Project Donor. According to the U.S. Health Resources and Services Administration, more than 109,000 people are awaiting an organ transplant, and of those roughly 95,000 need a kidney transplant. The need for kidney transplants greatly outweighs the supply: In 2023, the Association of Organ Procurement Organizations found that nearly 4,000 individuals in the U.S. passed away while waiting for a kidney donation. Unlike many other organs, kidney donations can come from living or deceased individuals. Willing individuals may donate a kidney to those in need if they meet certain criteria. For example, donation centers typically require donors to abstain from smoking for a sufficient amount of time, as smoking increases the risk of surgical complications to both the donor and the recipient. With Global Action's grant, The University of Chicago will expand smoking cessation assistance for donors who smoke with the goal of increasing the number of kidney transplants. "By offering resources to adults who smoke, this grant work will potentially extend the lives of two major groups: those who can finally receive a kidney donation, and those who are empowered to successfully quit smoking," said Pamela Parizek, Board Chair of Global Action to End Smoking. Global Action's grant will increase the reach of Project Donor, a pilot program created by The University of Chicago. Previously, Project Donor has supported over 2,000 individuals in making lifestyle modifications, such as smoking cessation, to become a living donor, resulting in 240 successful living donations. "We are excited to work with Global Action to support more prospective living donors on their path to stop smoking," said Josie Maier, the Director of Project Donor. "By quitting smoking, prospective donors can become eligible for organ donation and save the life of someone they care about." With Global Action's support, Project Donor will help more potential donors quit smoking and become eligible to donate. The grant work includes creating donor-specific case management training, providing access to additional counseling, distributing free nicotine replacement therapies or other tobacco harm reduction tools where appropriate, and embedding automated referrals to increase the program's reach. Project Donor also will partner with up to 160 U.S. transplant centers to ensure that any potential donors disqualified for smoking are connected to cessation and harm reduction resources as appropriate. "Collectively, public health has made many strides in ending combustible tobacco use, which remains the leading preventable cause of death," said Parizek. "Our grant work with The University of Chicago and Project Donor demonstrates the creative approach we're taking to assist all adults who smoke to quit." Is smoking still a public health problem? Smoking rates have declined over the last 40 years, but progress has stagnated. Roughly 20% of adults across the globe continue to smoke. In the U.S., the smoking rate remains just under 10%. However, smoking rates are disproportionately high in certain populations, including those who live with mental health conditions, substance use disorders or chronic disease; identify as people of color or indigenous people; live in poverty; and/or are members of the LGBTQIA+ community. Why is smoking so dangerous? Smoking a cigarette burns tobacco, which releases thousands of chemicals into the lungs. Many of these chemicals are known to cause long-term health problems, including cancer, heart disease, reproductive challenges, and more. Nicotine is a highly addictive stimulant found in tobacco. Though it is not as dangerous as many of the other chemicals found in cigarettes, it is what makes smoking extremely difficult to quit. Traditional smoking cessation tools include nicotine replacement therapies like gum, patches, or lozenges. Counseling and medications can also help a person who would like to quit. However, if a person can't or won't quit smoking with these approaches, less harmful products containing nicotine may be appropriate tools to help adults who smoke to quit. What is tobacco harm reduction? Tobacco harm reduction is a specific form of harm reduction applied to people who smoke combustible cigarettes. Harm reduction is a concept in public health that acknowledges that certain activities have high risks, and that there are ways to modify these activities to reduce these risks. It is a term that first became common in public health in the 1980s. Examples of harm reduction include providing clean needles for those who use IV drugs, condoms for those who engage in sexual activity, or seatbelts for those riding in a car. Tobacco harm reduction is the concept that for those adults who cannot or will not quit smoking using traditional cessation tools, switching entirely to reduced-risk nicotine options can lower their long-term health risks and help them live longer, healthier lives. These products include e-cigarettes, nicotine pouches, or heated tobacco products. These products aren't entirely safe, but they don't contain as many of the harmful chemicals found in cigarettes. Many health authorities, including the U.S. Food and Drug Administration and the UK's National Health Service, recognize the potential benefit of these tools for adults who smoke. The U.S. FDA has authorized certain reduced-risk nicotine products as less harmful alternative for adults who smoke and switch completely. The UK's NHS states that e-cigarettes can help people who smoke quit and are significantly less risky than cigarettes. What is Global Action to End Smoking? Global Action to End Smoking is a 501(c)(3) charitable grantmaking organization. Our mission is to end combustible tobacco use, which remains the leading preventable cause of death globally. We are accelerating comprehensive, science-based global efforts to end the smoking epidemic. We support all adults who smoke on their unique journeys to quit—no matter where they live or what identities they carry. We want all adults who smoke to feel respected. We understand each person's quit journey is as unique as they are, and their trust must be earned through empathy. Media Contact: Katherine Ellen Foley, Senior Director, Communications 202-215-9971 [email protected] SOURCE Global Action to End Smoking 21% more press release views with Request a Demo

07 Sep 2026

·www.prnewswire.com

Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction

Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand, Sept. 6, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced the peer-reviewed publication of interim results from its ongoing MASTRR Registry, reporting low infection rates and no adverse events definitely related to Myriad products. Published in Advances in Therapy, the interim analysis included 411 patients and 474 soft tissue defects treated across 10 US centers. To Aroa's knowledge, it is the largest published prospective analysis of a bioscaffold in in-patient soft tissue reconstruction. Myriad Matrix™ and Myriad Morcells™ were evaluated across a broad range of complex soft tissue reconstruction procedures in a highly challenging real-world patient population. Approximately 59% of patients were ASA Class III or IV, indicating significant underlying systemic disease. In addition, 35% had diabetes, 30% had vascular disease and 23% used nicotine. The defects were similarly complex, with approximately 89% clean-contaminated or contaminated, 59% chronic, 15% involving confirmed osteomyelitis and 11% involving exposed structures, including bone, tendon or viscera. Despite this complexity, deep tissue infection occurred in only 0.7% of patients and superficial infection in 2.9%. No infections were attributed to Myriad over a median follow-up period of 27 weeks. Across the 474 defects, the median number of Myriad applications was one. Aroa CEO Brian Ward said the publication marks an important milestone for Myriad and the MASTRR Registry. "This is an important milestone for Myriad and the MASTRR Registry. AROA is lifting the bar for the quality of clinical evidence in soft tissue reconstruction," Mr Ward said. "As the largest published prospective analysis of a bioscaffold in this field that we are aware of, the study provides a substantial dataset encompassing 411 patients and 474 complex soft tissue defects. "Despite the challenging patient population, infection rates were exceptionally low, and no adverse events were causally related to Myriad. It is also encouraging to see the authors note the infection profile compared very favourably with other commercially available bioscaffolds, as we see this as a key differentiator." The authors of the interim analysis discussed Myriad's low infection rates in the context of infection rates reported for several resorbable synthetic bioscaffold products used in complex soft tissue reconstruction, as reported in separately published meta-analyses. Those reported infection rates ranged from 16% to 25%. Post-operative infections can delay healing, increase the risk of further complications and may require additional treatments, surgical interventions or hospitalization. A large US analysis of patients undergoing open surgical procedures found that a surgical site infection added an average 7.8–9.3 days to a patient's hospital stay and approximately US$18,600–US$21,000 in healthcare costs, with deep tissue infections creating an even greater burden.[1] While the MASTRR interim analysis assessed safety rather than healthcare utilization or cost savings, Aroa said Myriad's favourable infection profile may be relevant to healthcare providers managing complex soft tissue defects. The MASTRR Registry is an ongoing prospective, multicenter observational study evaluating the real-world safety and performance of Myriad Matrix and Myriad Morcells. More than 550 patients are currently enrolled, and the registry is approved to enroll up to 800 patients across 15 US sites. The publication adds to previously published procedure-specific analyses from the MASTRR Registry in lower extremity reconstruction, trauma, burns, pilonidal disease and pressure injuries. Aroa expects the expanding registry dataset to support further analyses across multiple surgical specialties and applications. Aroa said the findings support the growing body of clinical evidence for Myriad and build on the product's strong commercial momentum, following 54% sales growth in FY26. The study, Safety of Ovine Forestomach Matrix Across 474 Soft Tissue Defects: Interim Results from the Prospective Multicenter MASTRR Registry, has been published in Advances in Therapy and is available online here About AROA Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix bioscaffold derived from ovine (sheep) forestomach. Over 7.5 million AROA devices have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). SOURCE Aroa Biosurgery 21% more press release views with Request a Demo

Clinical Result

07 Sep 2026

·www.biospace.com

Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction

Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand , Sept. 6, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced the peer-reviewed publication of interim results from its ongoing MASTRR Registry, reporting low infection rates and no adverse events definitely related to Myriad products. Published in Advances in Therapy , the interim analysis included 411 patients and 474 soft tissue defects treated across 10 US centers. To Aroa's knowledge, it is the largest published prospective analysis of a bioscaffold in in-patient soft tissue reconstruction. Myriad Matrix™ and Myriad Morcells™ were evaluated across a broad range of complex soft tissue reconstruction procedures in a highly challenging real-world patient population. Approximately 59% of patients were ASA Class III or IV, indicating significant underlying systemic disease. In addition, 35% had diabetes, 30% had vascular disease and 23% used nicotine. The defects were similarly complex, with approximately 89% clean-contaminated or contaminated, 59% chronic, 15% involving confirmed osteomyelitis and 11% involving exposed structures, including bone, tendon or viscera. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Despite this complexity, deep tissue infection occurred in only 0.7% of patients and superficial infection in 2.9%. No infections were attributed to Myriad over a median follow-up period of 27 weeks. Across the 474 defects, the median number of Myriad applications was one. Aroa CEO Brian Ward said the publication marks an important milestone for Myriad and the MASTRR Registry. "This is an important milestone for Myriad and the MASTRR Registry. AROA is lifting the bar for the quality of clinical evidence in soft tissue reconstruction," M r Ward said. "As the largest published prospective analysis of a bioscaffold in this field that we are aware of, the study provides a substantial dataset encompassing 411 patients and 474 complex soft tissue defects. ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); "Despite the challenging patient population, infection rates were exceptionally low, and no adverse events were causally related to Myriad. It is also encouraging to see the authors note the infection pro very favourably with other commercially available bioscaffolds, as we see this as a key differentiator." The authors of the interim analysis discussed Myriad's low infection rates in the context of infection rates reported for several resorbable synthetic bioscaffold products used in complex soft tissue reconstruction, as reported in separately published meta-analyses. Those reported infection rates ranged from 16% to 25%. Post-operative infections can delay healing, increase the risk of further complications and may require additional treatments, surgical interventions or hospitalization. A large US analysis of patients undergoing open surgical procedures found that a surgical site infection added an average 7.8–9.3 days to a patient's hospital stay and approximately US$18,600–US$21,000 in healthcare costs, with deep tissue infections creating an even greater burden. [1] While the MASTRR interim analysis assessed safety rather than healthcare utilization or cost savings, Aroa said Myriad's favourable infection pro be relevant to healthcare providers managing complex soft tissue defects. ezstandalone.cmd.push(function () { ezstandalone.showAds(133); }); The MASTRR Registry is an ongoing prospective, multicenter observational study evaluating the real-world safety and performance of Myriad Matrix and Myriad Morcells. More than 550 patients are currently enrolled, and the registry is approved to enroll up to 800 patients across 15 US sites. The publication adds to previously published procedure-specific analyses from the MASTRR Registry in lower extremity reconstruction, trauma, burns, pilonidal disease and pressure injuries. Aroa expects the expanding registry dataset to support further analyses across multiple surgical specialties and applications. Aroa said the findings support the growing body of clinical evidence for Myriad and build on the product's strong commercial momentum, following 54% sales growth in FY26. The study, Safety of Ovine Forestomach Matrix Across 474 Soft Tissue Defects: Interim Results from the Prospective Multicenter MASTRR Registry , has been published in Advances in Therapy and is available online here ezstandalone.cmd.push(function () { ezstandalone.showAds(134); }); About AROA Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for every body '. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix bioscaffold derived from ovine (sheep) forestomach. Over 7.5 million AROA devices have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc. ezstandalone.cmd.push(function () { ezstandalone.showAds(135); }); Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). [1] Hou Y, Collinsworth A, Hasa F, Griffin L. Incidence, and impact of surgical site infections on length of stay and cost of care for patients undergoing open procedures. Surgery Open Science. View original content to download multimedia: SOURCE Aroa Biosurgery

Clinical Result

100 Deals associated with Nicotine

External Link

KEGG	Wiki	ATC	Drug Bank
D03365	Nicotine	N07BA01	DB00184

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Smoking Cessation	South Korea	SAEHAN PHARM	28 Aug 2007
Tobacco Use Disorder	Australia	Johnson & Johnson Pacific Pty Ltd.	27 Nov 2001
Nicotine Dependence	United States	Haleon US Capital LLC	13 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acral Lentiginous Malignant Melanoma	Phase 3	United States	McNeil AB	01 Mar 2011
Dyskinesia, Drug-Induced	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Parkinson Disease	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Lung Cancer	Phase 1	United States	Pfizer Inc.	16 Jun 2017
disorder of aging	Preclinical	China	The Shenzhen Institutes of Advanced Technology	07 Feb 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05206435 (SHINE, CTgov)	Phase 4	Nicotine Dependence	183	Electronic Cigarette (Electronic Cigarettes)	tkecmytjsd(znqfbjclrb) = wvcmvdvowx vatpapwrga (fyeumnjdss, .28) View more	-	20 Aug 2026
				Nicotine Lozenge (Nicotine Lozenges)	tkecmytjsd(znqfbjclrb) = vkjfsimfir vatpapwrga (fyeumnjdss, .24) View more
NCT01622998 (STEP, CTgov)	Phase 4	Smoking Cessation	303	NicoDerm Patch (Standard Transdermal NRT Group (UC))	yxirzdsjol = yhnyjcfywe hkgtzgmdim (awlmdccwoy, fetjysyans - mqmmqtlybj) View more	-	14 Aug 2026
				NicoDerm Patch (Titrated Transdermal NRT Group (EXP))	yxirzdsjol = zpcpydpqbr hkgtzgmdim (awlmdccwoy, lxzmevyvhn - mtxulalycz) View more
NCT00962988 (CTgov)	Phase 4	Stroke \| Ischemic Attack, Transient \| Smoking Cessation ... View more	194	Cost-Free Pharmacotherapy Group (Cost-Free Group)	hshronlnbz = lnmzgvrqxw iipaqamzca (rjzweislym, enwwqsymhw - ajsozsxcfy) View more	-	10 Aug 2026
				Prescription Only Group (Prescription Only Group)	hshronlnbz = dbzjilnina iipaqamzca (rjzweislym, ckkxqtdowi - oywmfmvphw) View more
NCT05004662 (CTgov)	Not Applicable	Smoking Cessation	502	Counseling+Nicotine patch (Standard Treatment)	yzezlxckme = eauskkozho itzaylythb (gtkmcgessm, parlttkwai - pfkanfwhkl) View more	-	04 Aug 2026
				Nicotine patch+Smartphone-delivered automated treatment (Automated Treatment)	yzezlxckme = ezxzxexdtb itzaylythb (gtkmcgessm, kmcmpndunk - dtwwlycsid) View more
NCT05130788 (CTgov)	Not Applicable	Smoking Cessation	150	Nicotine Replacement Therapy (NRT) (Intervention Group A (Aim 2))	txyywhssxb = hfwopwecii qnjfnygdnm (ivlfxygubq, dzapwneyye - rbgitbzrlt) View more	-	31 Jul 2026
				Nicotine Replacement Therapy (NRT) (Control Group (Aim 2))	owdpxebvqp = elmledrirv kjrxxmclml (ikttjwculb, xazjskjqzo - skazezkuhx) View more
NCT03691350 (CTgov)	Early Phase 1	-	66	Bronchoscopy with Bronchoalveolar Lavage (Group I (Usual Cigarette Brand))	kiqjxrutda(uudqvhtqnl) = syegwwmcfr qhkpocjfyg (hgweudawrs, 0.3059) View more	-	23 Apr 2026
				Electronic Cigarette (Group II (SREC With Nicotine))	kiqjxrutda(uudqvhtqnl) = sbtfiucslv qhkpocjfyg (hgweudawrs, 0.2939) View more
NCT06051474 (CTgov)	Phase 4	Smoking Cessation \| Smoking \| Nicotine Dependence	23	Nicotine Replacement Product	yqqhfzvswc = qczkqkqbjb kwpzxvtope (ogukypfune, epsxvqcaor - cokbvcipiz) View more	-	16 Apr 2026
NCT03652740 (CTgov)	Phase 1	-	25	Placebo+Nicotine+Methylphenidate (Caffeine Chooser)	yetmasuxnh(ybtcfszfrm) = cdinwtkzbn utqamaljjq (klzzdkhlpr, 1.20) View more	-	02 Feb 2026
				Placebo+Nicotine+Methylphenidate (Caffeine Non-Chooser)	yetmasuxnh(ybtcfszfrm) = ogdfowtqmp utqamaljjq (klzzdkhlpr, 0.60) View more
NCT04965181 (CTgov)	Not Applicable	Smoking	504	Mindfulness-Based Addiction Treatment+Nicotine Replacement Therapy (Mindfulness-based Addiction Treatment (MBAT) + iQuit Mindfully)	rducnuivaz = iqvntnmvqc htpvvgvruk (bskqkdkokm, wgozhfptyw - ghgcjehjru) View more	-	30 Dec 2025
				Self-help materials+Nicotine Replacement Therapy (iQuit Mindfully)	rducnuivaz = hlaerlhkye htpvvgvruk (bskqkdkokm, smtphtufvy - imkvwpajxh) View more
NCT06289192 (CTgov)	Phase 4	Lung Cancer \| Tobacco Use Disorder	5	Lung Cancer Screening+Nicotine Replacement Product	msvcjokkvj = kobbkocbcy giimfmiofd (rmvjeqmsaf, muvxtivzsa - qyqhmjrljo) View more	-	10 Sep 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis